Skip to main content
. 2015 Feb 28;6(13):11295–11309. doi: 10.18632/oncotarget.3123

Figure 2. Cytotoxic effect of Bevacizumab and Sunitinib on CSC-derived endothelial cells.

Figure 2

Panel A and B. Effect of 1–10 μM Sunitinib (S1-S10) and of 25–250 μg/ml Bevacizumab (B25-B250) on proliferation (A) and apoptosis (B) of B-CSC and R-CSC before (Undiff, black columns) and after the endothelial differentiation (Diff., white columns). Panel C and D. The effect of Bevacizumab and Sunitinib on endothelial differentiated CSC was compared to that on total breast tumor-derived endothelial cells (BTEC) or on normal endothelial cells (HUVEC). Data are mean ± SD of five different experiments (A and B) or three different experiments (C and D). Student's t test was performed: **= p < 0.001, *= p < 0.05 drug treated vs CTL cells.